Skip to main content
    H

    Haemonetics Corporation (HAE)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $121.40
    -1.54 (-1.25%)

    Market Cap: $5.60B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Haemonetics Corporation (HAE) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Haemonetics (HAE) is expected to report earnings on Feb 3, 2027. In the quarter ended Sep 30, 2026, Haemonetics reported EPS of $1.35, above the $1.30 estimate. It beat the EPS estimate in each of the last 20 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    90%(36/40)
    Avg Surprise
    +10.82%
    Streak
    20 Q

    Upcoming Estimates

    Reports Feb 3, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$1.27
    Range$1.16 - $1.43
    12 analysts
    EPS Revisions
    0
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$1.36-6.5%
    60d ago$1.36-6.5%
    30d ago$1.37-6.8%
    7d ago$1.29-1.4%
    Current$1.27
    Revenue Consensus
    $357.79M
    Range$351.72M - $366.60M
    10 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$1.58
    Range$1.41 - $1.74
    13 analysts
    Revenue Consensus
    $385.92M
    Range$351.58M - $414.89M
    13 analysts

    Next Report

    HAE has an expected report date of Feb 3, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 3.1% below the $1.31 reported for the quarter ended Dec 31, 2025.

    HAE Earnings Call

    The latest HAE earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, HAE beat 36, missed 3 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $357.76M, up 9.3% from $327.31M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$1.35$1.30$1.21 - $1.37+3.85%Beat+6.3%111 up, 0 downNov 5, 2026$357.76M
    Jun 30, 2026$1.14$1.07$1.02 - $1.14+6.54%Beat+3.6%111 up, 1 downAug 6, 2026$339.38M
    Mar 31, 2026$1.29$1.27$1.25 - $1.31+1.57%Beat+4.0%112 up, 8 downMay 7, 2026$346.35M
    Dec 31, 2025$1.31$1.25$1.18 - $1.28+4.80%Beat+10.1%113 up, 8 downFeb 5, 2026$338.97M
    Sep 30, 2025$1.27$1.11$1.07 - $1.16+14.41%Beat+13.4%111 up, 0 downNov 6, 2025$327.31M
    Jun 30, 2025$1.10$1.01$0.95 - $1.10+8.91%Beat+7.8%100 up, 1 downAug 7, 2025$321.39M
    Mar 31, 2025$1.24$1.22$1.17 - $1.28+1.64%Beat+37.8%10N/AMay 8, 2025$330.60M
    Dec 31, 2024$1.19$1.17$1.12 - $1.21+1.71%Beat+14.4%100 up, 1 downFeb 6, 2025$348.54M
    Sep 30, 2024$1.12$1.07$1.03 - $1.10+4.67%Beat+13.1%100 up, 0 downNov 7, 2024$345.51M
    Jun 30, 2024$1.02$1.01$0.95 - $1.07+0.99%Beat-2.9%70 up, 0 downAug 8, 2024$336.17M
    Mar 31, 2024$0.90$0.89$0.88 - $0.92+1.12%Beat+16.9%70 up, 0 downMay 9, 2024$343.29M
    Dec 31, 2023$1.04$0.94$0.91 - $1.00+10.64%Beat+22.4%70 up, 0 downFeb 8, 2024$336.25M
    Sep 30, 2023$0.99$0.89$0.83 - $0.97+11.24%Beat+19.3%70 up, 0 downNov 2, 2023$318.18M
    Jun 30, 2023$1.05$0.73$0.67 - $0.84+43.84%Beat+81.0%80 up, 0 downAug 8, 2023$311.33M
    Mar 31, 2023$0.77$0.70$0.63 - $0.74+10.00%Beat+18.5%80 up, 0 downMay 11, 2023$304.42M
    Dec 31, 2022$0.85$0.82$0.72 - $0.89+3.66%Beat+1.2%81 up, 0 downFeb 7, 2023$305.30M
    Sep 30, 2022$0.83$0.67$0.63 - $0.72+23.88%Beat+38.3%81 up, 0 downNov 7, 2022$297.49M
    Jun 30, 2022$0.58$0.51$0.43 - $0.58+13.73%Beat+16.0%71 up, 0 downAug 10, 2022$261.46M
    Mar 31, 2022$0.65$0.60$0.56 - $0.62+8.33%Beat+41.3%70 up, 0 downMay 10, 2022$265.00M
    Dec 31, 2021$0.84$0.73$0.67 - $0.80+15.07%Beat+3.7%82 up, 1 downFeb 8, 2022$259.77M
    Sep 30, 2021$0.60$0.61$0.49 - $0.67-1.64%Miss-3.2%8N/ANov 9, 2021$239.90M
    Jun 30, 2021$0.50$0.45$0.31 - $0.57+11.11%Beat+8.7%7N/AAug 11, 2021$228.53M
    Mar 31, 2021$0.46$0.67$0.60 - $0.71-31.34%Miss-33.3%7N/AMay 13, 2021$225.03M
    Dec 31, 2020$0.81$0.65$0.56 - $0.71+24.62%Beat-13.8%7N/AFeb 2, 2021$240.37M
    Sep 30, 2020$0.62$0.51$0.45 - $0.59+21.57%Beat-28.7%7N/ANov 4, 2020$209.49M
    Jun 30, 2020$0.46$0.41$0.32 - $0.55+12.20%Beat-43.2%7N/AAug 4, 2020$195.58M
    Mar 31, 2020$0.69$0.73$0.67 - $0.77-5.48%Miss+13.1%7N/AMay 5, 2020$238.49M
    Dec 31, 2019$0.94$0.76$0.73 - $0.82+23.68%Beat+49.2%7N/AFeb 4, 2020$258.97M
    Sep 30, 2019$0.87$0.72$0.56 - $0.74+20.83%Beat+55.4%7N/ANov 1, 2019$252.57M
    Jun 30, 2019$0.81$0.64$0.60 - $0.67+26.56%Beat+37.3%7N/AAug 6, 2019$238.45M
    Mar 31, 2019$0.61$0.55$0.52 - $0.57+10.91%Beat+41.9%7N/AMay 7, 2019$249.29M
    Dec 31, 2018$0.63$0.59$0.57 - $0.61+6.78%Beat+1.6%7N/AFeb 5, 2019$247.36M
    Sep 30, 2018$0.56$0.54$0.50 - $0.57+3.70%Beat+16.7%7N/ANov 6, 2018$241.58M
    Jun 30, 2018$0.59$0.42$0.37 - $0.47+40.48%Beat+78.8%8N/AAug 7, 2018$229.35M
    Mar 31, 2018$0.43$0.43$0.40 - $0.460.00%In line+10.3%8N/AMay 8, 2018$233.55M
    Dec 31, 2017$0.62$0.44$0.41 - $0.46+40.91%Beat+44.2%8N/AFeb 6, 2018$234.04M
    Sep 30, 2017$0.48$0.41$0.38 - $0.46+17.07%Beat+4.3%8N/ANov 7, 2017$225.38M
    Jun 30, 2017$0.33$0.30$0.25 - $0.37+10.00%Beat+32.0%8N/AAug 7, 2017$210.95M
    Mar 31, 2017$0.39$0.38N/A+2.63%Beat+5.4%N/AN/AMay 8, 2017$228.07M
    Dec 31, 2016$0.43$0.40N/A+7.50%Beat-10.4%N/AN/AFeb 6, 2017$227.84M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Mar 31, 2026 was $4.97, up 8.8% from the year before. It was $1.53 for the year ended Mar 31, 2017, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Mar 31, 2026$4.97+8.8%
    Mar 31, 2025$4.57+14.8%
    Mar 31, 2024$3.98+31.4%
    Mar 31, 2023$3.03+17.0%
    Mar 31, 2022$2.59+10.2%
    Mar 31, 2021$2.35-29.0%
    Mar 31, 2020$3.31+38.5%
    Mar 31, 2019$2.39+28.5%
    Mar 31, 2018$1.86+21.6%
    Mar 31, 2017$1.53N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,200 words across 12 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,19312
    2026Q2Jun 30, 20266,32710
    2026Q1Mar 31, 20268,42914
    2025Q4Dec 31, 20259,27512
    2025Q3Sep 30, 202510,87813
    2025Q2Jun 30, 20258,39112
    2025Q1Mar 31, 20255,92410
    2024Q4Dec 31, 20249,04611

    2026Q3 Earnings Call

    Opening remarks

    Olga Guyette Vice President, Investor Relations and Treasury Good morning, and thank you for joining us for Haemonetics Third Quarter Fiscal Year 2026 Conference Call and Webcast. I'm joined today by Christopher Simon, our CEO, and James D'Arecca, our CFO. This morning, we released our third quarter and year-to-date fiscal 2026 results and updated full-year fiscal 2026 guidance. The materials, including our earnings release, Form 10-Q, and the supplemental earnings presentation, are available on our Investor Relations website and in this morning's press release. Before we begin, I'd like to remind everyone that we will use both reported and organic revenue growth rates that exclude the impact of FX, the divestiture of the whole blood product line, and the exit of certain liquid solution products. Organic Growth ex CSL also excludes the impact of the previously disclosed transition of CSL's US disposable business. We'll also refer to other non-GAAP financial measures to help investors understand Haemonetics' ongoing business performance. Please note that these measures exclude certain charges and income items. A full list of excluded items, reconciliations to our GAAP results, and comparisons with the prior year periods are provided in our earnings release. Our remarks today include forward-looking statements, and our actual results may differ materially from the anticipated results. Factors that may cause our results to differ include those referenced in the safe harbor statement in today's release, and in our other SEC filings. We do not undertake any obligation to update these forward-looking statements. And now I'd like to turn it over to Christopher Simon.

    Christopher Simon Chief Executive Officer (CEO) Thanks, Olga. Good morning, and thank you for joining us today. We delivered a strong quarter and we are raising our full-year revenue, earnings, and free cash flow guidance. Nexus and TEG delivered outsized growth driven by sustained share gains, innovation-based pricing, and durable end-market demand, demonstrating the strength and resilience of these core products and our increasingly productive operating model. Third-quarter revenue was $339 million, bringing year-to-date revenue to $988 million. Reported revenue reflects the $153 million impact of last year's portfolio transitions. Allowing for these nonrecurring items, underlying performance remains strong, with organic growth ex CSL of 8% in the quarter and 10% year-to-date. Adjusted earnings per share increased 10% in the quarter and 11% year-to-date to $1.31 and $3.67 per share, respectively, underscoring both the quality and the durability of our earnings. With that context, let's review our businesses in more detail. Hospital revenue was $144 million in the quarter and $429 million year-to-date, down 1% in the quarter and up 2% year-to-date organically, as strong performance in Blood Management Technologies offset softness in Interventional Technologies.

    Frequently Asked Questions About HAE

    When is Haemonetics's next earnings date?

    Haemonetics's next earnings report is expected for Feb 3, 2027.

    Did HAE beat earnings estimates last quarter?

    Yes. Haemonetics reported EPS of $1.35 for the quarter ended Sep 30, 2026, above the $1.30 estimate, a 3.85% surprise.

    What EPS do analysts expect from HAE next quarter?

    The consensus EPS estimate for Haemonetics for the quarter ending Dec 31, 2026 is $1.27 from 12 analysts, with estimates from $1.16 to $1.43.

    How often does HAE beat earnings estimates?

    Haemonetics beat the EPS estimate in each of the last 20 quarters, with an average surprise of +9.53%.